High Sodium for Hypernatremia

Phase-Based Progress Estimates
Hypernatremia+1 More
High Sodium - DietarySupplement
18 - 65
All Sexes
What conditions do you have?

Study Summary

This trial will study how high sodium diets affect the work of the heart by looking at changes in vascular function.

Eligible Conditions
  • Hypernatremia
  • Sodium Excess

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 3 Secondary · Reporting Duration: The morning of day 9 through the morning of day 10 for each arm.

On the 10th day of each arm.
Arterial Stiffness
Conduit artery endothelium-dependent dilation
Forward Pulse Wave Amplitude
Reflected Pulse Wave Amplitude
Wave reflection timing
Day 10
24 Hour Blood Pressure

Trial Safety

Safety Progress

1 of 3

Trial Design

2 Treatment Groups

High Sodium
1 of 2
1 of 2
Experimental Treatment
Non-Treatment Group

50 Total Participants · 2 Treatment Groups

Primary Treatment: High Sodium · Has Placebo Group · N/A

High Sodium
Experimental Group · 1 Intervention: High Sodium · Intervention Types: DietarySupplement
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: the morning of day 9 through the morning of day 10 for each arm.

Who is running the clinical trial?

University of DelawareLead Sponsor
133 Previous Clinical Trials
36,618 Total Patients Enrolled
1 Trials studying Hypernatremia
100 Patients Enrolled for Hypernatremia
David G Edwards, PhDPrincipal InvestigatorUniversity of Delaware
3 Previous Clinical Trials
169 Total Patients Enrolled

Eligibility Criteria

Age 18 - 65 · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: October 1st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.